Bayer Schering Pharma extends research in cancer-related targets

Published: 29-Jun-2009
Sustainability Research & Development

Bayer Schering Pharma of Germany has signed an exclusive licence agreement with California-based Celera that will give the company access to five cancer-related targets for therapeutic development and in-vivo diagnostic imaging. These therapeutic targets were identified by Celera's proteomics discovery platform.


Bayer Schering Pharma of Germany has signed an exclusive licence agreement with California-based Celera that will give the company access to five cancer-related targets for therapeutic development and in-vivo diagnostic imaging. These therapeutic targets were identified by Celera's proteomics discovery platform.

Bayer Schering Pharma will pay Celera a one-off fee for exclusive access to the five targets. Additional payments are due on achieving development and commercial milestones. Celera is entitled to royalties based on net sales of any commercialised product.

"This agreement allows us to expand our existing research portfolio in the area of cancer-related targets," said Professor Khusru Asadullah, head of target discovery at Bayer Schering Pharma. "We look forward to exploring the full potential of these promising target candidates with regard to therapeutic interference for anti-tumor therapy as well as in in-vivo diagnostic imaging."

  • Companies:
  • Bayer
See more

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Read more
Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation
  3. Olon releases its annual ESG report The Italian Group, leading international API supplier, presents the 2023 sustainability report and confirms the sustainability journey toward energy transition, investments in alternative energy sources, social and economic involvement and support for the communities in which it operates
  4. Syntegon offers certified CO2 calculation for its machine portfolio Syntegon offers companies in the pharmaceutical and food industries full transparency on the carbon footprint of all Syntegon machines with a software-based approach certified by TÜV Rheinland, a German Association for technical inspection
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer
Packaging

Bayer joins the Blister Pack Collective to reduce single-use plastics in tablet packs

PA Consulting (PA), the company bringing ingenuity to life, and PulPac, the Swedish R&D and IP company behind Dry Molded Fiber, are pleased to announce the Consumer Health division of Bayer has joined the Blister Pack Collective
Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Design & Build

Bayer chooses Fluor and GE Healthcare for new cell culture technology centre

Company will invest US$150 million in new California facility expected to be ready for clinical production in late 2021
Media

TissUse establishes a multi-organ model for risk assessment with Bayer

The biotechnology company has signed a collaboration agreement with the pharmaceutical and life sciences company to develop a liver-endocrine tissue assay
Drug Delivery

Bayer and DelSiTech link up to develop new ophthalmology drug delivery technology

Agreement highlights the potential of biodegradable silica material in demanding drug delivery applications
Research & Development

Casebia Therapeutics establishes operations in Cambridge (MA, USA)

Hiring is underway and efforts have begun on haematology and ophthalmology programmes
Subscribe now